Advertisement

Monoclonal Antibody Associated with Increased Bone Density in Osteoporosis — Physician’s First Watch

Medical News |
January 2, 2014

Monoclonal Antibody Associated with Increased Bone Density in Osteoporosis

By Joe Elia

Romosozumab, a monoclonal antibody against an inhibitor of bone formation, increases bone mineral density, a New England Journal of Medicine study finds.

In a phase 2 trial overseen by the drug makers, some 380 postmenopausal women with low bone mineral density were randomized to one of several regimens of romosozumab given subcutaneously monthly or quarterly; to alendronate; to teriparatide; or to placebo.

After treatment for a year, all doses of romosozumab were associated with increases in lumbar-spine bone density above baseline values — up to 11%, versus 4% with alendronate and 7% with teriparatide.

An editorialist writes that an ongoing phase 3 trial may answer questions about romosozumab's longer-term safety and efficacy.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement